Related Experiment Videos
Ophthalmic drug delivery systems--recent advances
1Laboratoire de Pharmacie Galénique, Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes, France.
Progress in Retinal and Eye Research
|April 16, 1998
Summary
New ophthalmic drug delivery systems aim to overcome rapid precorneal drug loss. Advanced formulations like polymeric gels, colloidal systems, cyclodextrins, and collagen shields enhance ocular drug bioavailability for better therapeutic outcomes.
Area of Science:
- Ophthalmology
- Pharmaceutics
- Drug Delivery Systems
Background:
- Eye-drops are the primary ophthalmic formulation (90%), but suffer from rapid precorneal drug loss, limiting bioavailability.
- Improving ocular drug delivery is crucial for effective ophthalmic treatments.
Purpose of the Study:
- To review and discuss advanced ophthalmic drug delivery systems beyond conventional eye-drops.
- To highlight innovations addressing rapid drug loss and enhancing ocular bioavailability.
Main Methods:
- Focus on polymeric gels (hydrogels, in situ gel-forming systems), colloidal systems (liposomes, nanoparticles), cyclodextrins, and collagen shields.
- Analysis of their mechanisms for sustained drug release and improved ocular penetration.
Main Results:
- Hydrogels offer moderate bioavailability improvement but can cause blurred vision; in situ systems provide sustained release.
- Colloidal systems and cyclodextrins enhance bioavailability, particularly for poorly soluble drugs, and improve corneal permeability.
- Collagen shields offer continuous drug delivery but face tolerance issues.
Conclusions:
- Ophthalmic drug delivery is evolving towards combined technologies to prolong ocular surface contact time and slow drug elimination.
- Combining delivery systems shows promise for improving the efficacy of previously non-efficacious treatments.